Effects of ackA, pta and poxB inhibition by antisense RNA on acetate excretion and recombinant beta interferon expression in Escherichia coli

authors:

avatar Mohammad Hossein Morowvat ORCID , *

Koomesh: Vol.22, issue 3; 505-517
article type: issue_documents_importer
received: July 05, 2019
accepted: November 02, 2019

how to cite: Morowvat M H. Effects of ackA, pta and poxB inhibition by antisense RNA on acetate excretion and recombinant beta interferon expression in Escherichia coli. koomesh. 2020;22(3):e153208. 

Abstract

Introduction: Escherichia coli (E.coli) is one of the most widely used hosts for the production of recombinant proteins. The main problem in getting high product yields and productivity is the accumulation of acetic acid (acetate) as an unwanted metabolic by-product. In this study, an antisense-based strategy as a metabolic engineering approach was employed to hamper the acetate excretion problem. Materials and Methods: A recombinant plasmid containing the encoding genes for human recombinant interferon beta (rhINF-β) and three antisense oligonucleotides against acetate kinase, phosphotransacetylase and pyruvate oxidase B was designed. The effects of recombinant plasmid on the cell physiology, rhINF-β production and acetate excretion were studied in E. coli. Results: The mRNA levels of the targeted enzymes were lowered in antisense-regulated cells compared to the control cells. The concentration of acetate in culture media was decreased due to the constructed plasmid. The expression of antisense RNA did not affect the cell growth, negatively. Besides, the rhINF-β production was enhanced in antisense-regulated strain compared to the control plasmid without antisense genes. Conclusion: Application of an antisense strategy on the acetate pathway was successful in metabolically engineering E. coli. This enhancement of production yield by antisense technology suggests that this strategy may be successfully applied to high cell density fermentations of E. coli expression system to overexpress other recombinant proteins.

References

  • 1.

    Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol 2018; 36: 1136-1145.

  • 2.

    Yin J, Li G, Ren X, Herrler G. Select what you need: A comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol 2007; 127: 335-347.

  • 3.

    Collins JH, Young EM. Genetic engineering of host organisms for pharmaceutical synthesis. Curr Opin Biotechnol 2018; 53: 191-200.

  • 4.

    Rahimpour SA, Najaei A, Mahboudi F. Efficiency of translation and post-translation regulatory genes in optimization of tissue plaminogen activator gene expression. Koomesh 2015; 17: 196-203. (Persian).

  • 5.

    Kaur J, Kumar A, Kaur J. Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. Int J Biol Macromol 2018; 106: 803-822.

  • 6.

    Jia B, Jeon CO. High-throughput recombinant protein expression in Escherichia coli: Current status and future perspectives. Open Biol 2016; 6: 160196.

  • 7.

    Slouka C, Kopp J, Spadiut O, Herwig C. Perspectives of inclusion bodies for bio-based products: Curse or blessing? Appl Microbiol Biotechnol 2019; 103: 1143-1153.

  • 8.

    Ann J, Maldonado B, Van Impe J, Van Mellaert L, Bernaerts K. Recombinant protein production and streptomycetes. J Biotechnol 2012; 158: 159-167.

  • 9.

    Schwarz H, Schmittner M, Duschl A, Horejs-Hoeck J. Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells. PloS One 2014; 9: e113840-e113840.

  • 10.

    Zhang L, Chou CP, Moo-Young M. Disulfide bond formation and its impact on the biological activity and stability of recombinant therapeutic proteins produced by Escherichia coli expression system. Biotech Adv 2011; 29: 923-929.

  • 11.

    Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotech Adv 2009; 27: 297-306.

  • 12.

    Anane E, Lpez C DC, Neubauer P, Cruz Bournazou MN. Modelling overflow metabolism in Escherichia coli by acetate cycling. Biochem Eng J 2017; 125: 23-30.

  • 13.

    Enjalbert B, Millard P, Dinclaux M, Portais JC, Ltisse F. Acetate fluxes in Escherichia coli are determined by the thermodynamic control of the Pta-AckA pathway. Sci Rep 2017; 7: 42135.

  • 14.

    De Mey M, De Maeseneire S, Soetaert W, Vandamme E. Minimizing acetate formation in E. coli fermentations. J Ind Microb Biotechnol 2007; 34: 689-700.

  • 15.

    Eiteman A, Altman E. Overcoming acetate in Escherichia coli recombinant protein fermentations. Trend Biotechnol 2006; 24: 530-536.

  • 16.

    Bernal V, Castao-Cerezo S, Cnovas M. Acetate metabolism regulation in Escherichia coli: Carbon overflow, pathogenicity, and beyond. Appl Microbiol Biotechnol 2016; 100: 8985-9001.

  • 17.

    Zeng H, Yang A. Modelling overflow metabolism in Escherichia coli with flux balance analysis incorporating differential proteomic efficiencies of energy pathways. BMC Syst Biol 2019; 13: 3.

  • 18.

    Hallaji M, Parhamfar M, Raoufi E, Abtahi H. Cloning, expression and purification of Escherichia coli modified phtase. Koomesh 2017; 20: 145-151. (Persian).

  • 19.

    Morzhakova AA, Skorokhodova AY, Gulevich AY, Debabov VG. Recombinant Escherichia coli strains deficient in mixed acid fermentation pathways and capable of rapid aerobic growth on glucose with a reduced crabtree effect. Appl Biochem Microbiol 2013; 49: 113-119.

  • 20.

    Xu B, Jahic M, Blomsten G, Enfors SO. Glucose overflow metabolism and mixed-acid fermentation in aerobic large-scale fed-batch processes with Escherichia coli. Appl Microbiol Biotechnol 1999; 51: 564-571.

  • 21.

    Luli GW, Strohl WR. Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations. Appl Env Microbiol 1990; 56: 1004-1011.

  • 22.

    Matsuoka Y, Shimizu K. Catabolite regulation analysis of Escherichia coli for acetate overflow mechanism and co-consumption of multiple sugars based on systems biology approach using computer simulation. J Biotechnol 2013; 168: 155-173.

  • 23.

    Deutscher J, Francke C, Postma PW. How phosphotransferase system-related protein phosphorylation regulates carbohydrate metabolism in bacteria. Microbiol Mol Biol Rev 2006; 70: 939-1031.

  • 24.

    McCleary WR, Stock JB. Acetyl phosphate and the activation of two-component response regulators. J Biol Chem 1994; 269: 31567-31572.

  • 25.

    Shimizu K, Matsuoka Y. Regulation of glycolytic flux and overflow metabolism depending on the source of energy generation for energy demand. Biotech Adv 2019; 37: 284-305.

  • 26.

    Bakhtiari N, Mirshahi M, Babaeipour V, Maghsoudi N, Tahzibi A. Down regulation of ackA-pta pathway in Escherichia coli BL21 (DE3): A step toward optimized recombinant protein expression system. Jundishapur J Microbiol 2014; 7: e8990. (Persian).

  • 27.

    Kim JY, Cha HJ. Down-regulation of acetate pathway through antisense strategy in Escherichia coli: Improved foreign protein production. Biotechnol Bioeng 2003; 83: 841-853.

  • 28.

    Chang DE, Shin S, Rhee JS, Pan JG. Acetate metabolism in a pta mutant of Escherichia coli W3110: Importance of maintaining acetyl coenzyme A flux for growth and survival. J Bacteriol 1999; 181: 6656-6663.

  • 29.

    Hahm DH, Pan J, Rhee JS. Characterization and evaluation of a pta (phosphotransacetylase) negative mutant of Escherichia coli HB101 as production host of foreign lipase. Appl Microbiol Biotechnol 1994; 42: 100-107.

  • 30.

    Kleman GL, Strohl WR. Acetate metabolism by Escherichia coli in high-cell-density fermentation. Appl Env Microbiol 1994; 60: 3952-3958.

  • 31.

    Wolfe AJ. The acetate switch. Microbiol Mol Biol Rev 2005; 69: 12-50.

  • 32.

    Castano-Cerezo S, Pastor J, Renilla S, Bernal V, Iborra J, Canovas M. An insight into the role of phosphotransacetylase (pta) and the acetate/acetyl-CoA node in Escherichia coli. Microb Cell Fact 2009; 8: 54.

  • 33.

    Bauer KA, Ben-Bassat A, Dawson M, De La Puente VT, Neway JO. Improved expression of human interleukin-2 in high-cell-density fermentor cultures of Escherichia coli K-12 by a phosphotransacetylase mutant. Appl Env Microbiol 1990; 56: 1296-1302.

  • 34.

    Contiero J, Beatty C, Kumari S, DeSanti CL, Strohl WR, Wolfe A. Effects of mutations in acetate metabolism on high-cell-density growth of Escherichia coli. J Ind Microbiol Biotechnol 2000; 24: 421-430.

  • 35.

    Shiloach J, Kaufman J, Guillard AS, Fass R. Effect of glucose supply strategy on acetate accumulation, growth, and recombinant protein production by Escherichia coli BL21 (DE3) and Escherichia coli JM109. Biotechnol Bioeng 1996; 49: 421-428.

  • 36.

    Marisch K, Bayer K, Cserjan-Puschmann M, Luchner M, Striedner G. Evaluation of three industrial Escherichia coli strains in fed-batch cultivations during high-level SOD protein production. Microb Cell Fact 2013; 12: 58.

  • 37.

    Van De Walle M, Shiloach J. Proposed mechanism of acetate accumulation in two recombinant Escherichia coli strains during high density fermentation. Biotechnol Bioeng 1998; 57: 71-78.